Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galiximab in Relapsed/Refractory Follicular Lymphoma
NCT00575068Phase 2Completed
- Sponsor
- Biogen
- Start
- Jan 2002
- Primary completion
- Sep 2002
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of galiximab in follicular lymphoma (FL), sponsored by Biogen. Primary endpoint: Safety profile of IDEC-114. Started Jan 2002; status: completed.
02
Drugs
galiximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00575068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00575068.